A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)

  • Dev, Anouk (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/52357/SVHM-2019-172768(v2)
NMA SSA Reference Number: SSA/52357/MonH-2019-179151(v1)
Monash Health Ref Number: RES-19-0000-482X
Effective start/end date26/07/1925/07/24


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • liver cancer